Literature DB >> 19002551

Haemochromatosis gene frequency in a control and diabetic Irish population.

L Kirk1, J Bird, S Ramadan, A Samad, G Adebayo, W Lourens, J Williams.   

Abstract

BACKGROUND: Hereditary haemochromatosis is inherited in an autosomal recessive manner. Two major mutations have been identified and the condition is emerging as one of the most common recessive mutations among subjects of Northern European descendants. AIM: This study investigated the prevalence of C282Y, H63D and S65C (three mutations of clinical significance for haemochromatosis), in a diabetic and control population from the North West of Ireland.
METHODS: DNA was extracted from whole blood samples of 249 known diabetics and 249 controls and assayed for the three genetic variants (C282Y, H63D and S65C).
RESULTS: The incidence for C282Y homozygosity is higher in the control population (1 in 83) when compared to the diabetic group (1 in 249). However, this is not statistically significant. S65C heterozygosity occurs with an incidence of 1 in 32 in control individuals and 1 in 124 in the diabetic population. The prevalence of the H63D mutation was similar in both populations.
CONCLUSION: For the three haemochromatosis mutations, there was no significant difference between the control group and the diabetic populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002551     DOI: 10.1007/s11845-008-0248-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  13 in total

Review 1.  EASL International Consensus Conference on Haemochromatosis.

Authors:  P Adams; P Brissot; L W Powell
Journal:  J Hepatol       Date:  2000-09       Impact factor: 25.083

2.  Haemochromatosis gene mutations in Finns, Swedes and Swedish Saamis.

Authors:  L E Beckman; K Sjöberg; S Eriksson; L Beckman
Journal:  Hum Hered       Date:  2001       Impact factor: 0.444

3.  Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls.

Authors:  P Holmström; J Marmur; G Eggertsen; M Gåfvels; P Stål
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

4.  A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment.

Authors:  S M McDonnell; B L Preston; S A Jewell; J C Barton; C Q Edwards; P C Adams; R Yip
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

Review 5.  Clinical aspects of hemochromatosis.

Authors:  Jillian O'Neil; Lawrie Powell
Journal:  Semin Liver Dis       Date:  2005-11       Impact factor: 6.115

6.  Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study.

Authors:  C Ellervik; T Mandrup-Poulsen; B G Nordestgaard; L E Larsen; M Appleyard; M Frandsen; P Petersen; P Schlichting; T Saermark; A Tybjaerg-Hansen; H Birgens
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

7.  A search for association between hereditary hemochromatosis HFE gene mutations and type 2 diabetes mellitus in a Polish population.

Authors:  Maciej T Małecki; Tomasz Klupa; Małgorzata Waluś; Wojciech Czogała; Paul Greenlaw; Jacek Sieradzki
Journal:  Med Sci Monit       Date:  2003-02

8.  Hemochromatosis in Ireland and HFE.

Authors:  E Ryan; C O'keane; J Crowe
Journal:  Blood Cells Mol Dis       Date:  1998-12       Impact factor: 3.039

9.  Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in Southern Scandinavia and spread with the Vikings.

Authors:  N Milman; P Pedersen
Journal:  Clin Genet       Date:  2003-07       Impact factor: 4.438

Review 10.  Hereditary hemochromatosis--a new look at an old disease.

Authors:  Antonello Pietrangelo
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  1 in total

Review 1.  Twenty-Five Years of Contemplating Genotype-Based Hereditary Hemochromatosis Population Screening.

Authors:  Jörg Schmidtke
Journal:  Genes (Basel)       Date:  2022-09-09       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.